The introduction of novel potassium binders should allay these concerns [83, 84]
There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
doi: 10.1016/j.jot.2024.10.005 245 YangXChenYGuoJLiJZhangPYangHet al
Collins, StatPearls , Glucagon-like Peptide-1 Receptor Agonists
With its multifunctional benefits, glutathione is becoming a must-have ingredient in skincare routines across India
Either way, disclose all medications, comorbidities, and family history to your provider for thorough contraindication screening
